Genetic Susceptibility for Bronchopulmonary Dysplasia in Preterm Infants

Polymorphisms of Genes Controlling Alveolar Development and Risk of Bronchopulmonary Dysplasia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00904774

Acronym

GENBPD

Enrollment

800

Registered

2009-05-20

Start date

2009-05-31

Completion date

Unknown

Last updated

2009-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchopulmonary Dysplasia

Keywords

bronchopulmonary dysplasia, neonates, lung development, prematurity

Brief summary

Despite considerable obstetric and neonatal advances in the care of very low birth weight (VLBW) neonates, bronchopulmonary dysplasia (BPD) continues to occur among 20 to 40% of surviving infants, and new ways for combatting this disease must be found. BPD appears to result from arrested lung development, but its etiology has not yet been fully established. Besides the role of the exposure of the immature lung to injurious factors in the development of BPD, a genetic susceptibility for BPD in preterm infants was recently evidenced. Taking advantage of new genomic technologies, the objective of the investigators' project is to identify predisposing human genetic variants through: 1. a genome-wide association (GWA) study in VLBW neonates, 2. a candidate-gene association study, including selection of single nucleotide polymorphisms (SNPs) found in (a) and 3. functional studies of any SNP found to be convincingly associated with BPD in (a) and (b).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 8 Weeks

Healthy volunteers

Inclusion criteria

* Gestational age \< 28 weeks * Inborn birth * Prophylactic administration of surfactant in the delivery room * Written informed consent obtained from parents

Exclusion criteria

* Gestational age of 28 weeks or more * Outborn birth * No prophylactic administration of surfactant in the delivery room * Congenital malformation * Absence of written informed consent obtained from parents

Design outcomes

Primary

Measure	Time frame
bronchopulmonary dysplasia	36 weeks of postconceptional age

Countries

France

Outcome results